{
    "2020-11-24": [
        [
            {
                "time": "2021-03-15",
                "original_text": "Merck Sales Hit Hardest by Pandemic",
                "features": {
                    "keywords": [
                        "Merck",
                        "Sales",
                        "Hit",
                        "Pandemic"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-16",
                "original_text": "Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Evercore",
                        "ISI",
                        "HealthCONx",
                        "Conference"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-17",
                "original_text": "The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Gilead",
                        "Eli Lilly",
                        "Incyte",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-18",
                "original_text": "Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak",
                "features": {
                    "keywords": [
                        "Vir Biotech",
                        "CEO",
                        "Covid-19",
                        "Medicine",
                        "Promise",
                        "Outbreak"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-19",
                "original_text": "Should Value Investors Choose Eli Lilly and Co (LLY) Stock?",
                "features": {
                    "keywords": [
                        "Value Investors",
                        "Eli Lilly",
                        "Stock"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-20",
                "original_text": "Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Coronavirus",
                        "Treatment",
                        "Interim",
                        "Nod",
                        "Canada"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}